Ryght AI is building what it calls the world’s first “agentic AI platform” for clinical trials. The company’s system automates site selection, feasibility, budgeting, patient pre-screening, and even protocol authoring, areas that currently bog down timelines and strain sponsors, CROs, and research sites.
Over the past five years, AI has supercharged drug discovery. Algorithms now routinely identify new compounds, predict protein folding, and simulate early-stage efficacy, all in silico. Billions of dollars have poured into AI drug startups like Insitro, Xaira, and Genesis, promising faster, cheaper, and more precise development of new therapies.
Read more on AIJournal.com
By integrating Ryght AI's technology, Biorasi can provide their clients with real-time, site-specific data that leads to more intelligent site...
Press release announcing the company's rebranding from Synthetica Bio to Ryght with a focus on delivering trusted insights to biopharma.
Synthetica Bio taps into generative AI and strategic partnerships to revolutionize drug discovery. This innovation aims to empower biopharma...